title: Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia.
abstract: We analysed the long-term outcome of the L86 protocol using L-asparaginase (L-asp), vincristine (VCR) and prednisolone (PSL), collectively known as LVP or L97 protocol using LVP along with pirarubicin hydrochloride (THP-ADR) for 97 patients with acute lymphoblastic leukemia (ALL) diagnosed between 1986 and 2002. No significant differences were seen in the two protocols regarding the complete remission (CR) rate or survival. Seventy-five of the 97 patients (77%) achieved a CR. The overall survival (OS) and disease-free survival (DFS) rates were 32.1% and 30.4% at 10 years, respectively. By univariate analysis, we identified seven adverse factors for DFS which included the L2 subtype by French-American-British classification, hepatosplenomegaly, a white blood cell count of more than 30 x 10(9)/L, a blast cell count of more than 10 x 10(9)/L in the peripheral blood, hemoglobin concentration greater than 10 g/dL, a serum lactate dehydrogenase value greater than twice the upper limit of normal and the presence of the Philadelphia chromosome (Ph). According to multivariate analysis, only the presence of Ph was a significant unfavourable factor for DFS and OS. In the 30 patients under 35 years of age without Ph, the OS in the 20 patients treated with L86 and in the 10 patients treated with L97 were 48 and 86%, respectively (P = 0.011). These results indicate that intensified chemotherapy, such as the L97 protocol that includes an anthracycline, might be beneficial for younger patients who are Ph-negative.
authors.affiliation: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. ko-hide@land.linkclub.or.jp
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Koharazawa
authors.forename: Heiwa
authors.initials: H
authors.lastname: Kanamori
authors.forename: Rika
authors.initials: R
authors.lastname: Sakai
authors.forename: Chizuko
authors.initials: C
authors.lastname: Hashimoto
authors.forename: Sachiya
authors.initials: S
authors.lastname: Takemura
authors.forename: Michiko
authors.initials: M
authors.lastname: Hattori
authors.forename: Jun
authors.initials: J
authors.lastname: Taguchi
authors.forename: Katsumichi
authors.initials: K
authors.lastname: Fujimaki
authors.forename: Naoto
authors.initials: N
authors.lastname: Tomita
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fujita
authors.forename: Shin
authors.initials: S
authors.lastname: Fujisawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Harano
authors.forename: Koji
authors.initials: K
authors.lastname: Ogawa
authors.forename: Shigeki
authors.initials: S
authors.lastname: Motomura
authors.forename: Atsuo
authors.initials: A
authors.lastname: Maruta
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishigatsubo
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality* / Q000628:therapy*; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D014750:Vincristine; D011239:Prednisolone; D001215:Asparaginase